Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 16/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21872996 | 0.92 | PDPK1 (0.41) | PDPK1ALKFGFR1FGFR2FGFR4 | |
| SCHEMBL21872978 | 0.87 | CYP3A4 (0.42) | KDR | |
| SCHEMBL21873144 | 0.87 | KIT (0.43) | KDR | |
| SCHEMBL21873088 | 0.86 | PDPK1 (0.39) | PDPK1ALK | |
| SCHEMBL21873019 | 0.85 | CYP3A4 (0.43) | KDR | |
| SCHEMBL21873005 | 0.85 | CYP2C9 (0.39) | KDR | |
| SCHEMBL21873151 | 0.82 | AURKA (0.43) | FGFR1FGFR4KDR | |
| SCHEMBL21873020 | 0.79 | PDPK1 (0.40) | PDPK1ALK | |
| SCHEMBL21872977 | 0.77 | CYP2C9 (0.38) | KDR | |
| SCHEMBL22036854 | 0.77 | CSF1R (0.42) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-11-23 | — | — | US | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-05-07 | — | — | US | disclosed |
| EP-3643715-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140431-A1 | NITROGEN HETEROARYL DERIVATIVE HAVING CSF1R INHIBITORY ACTIVITY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSF1R, CSF3R, FSHR | PDPK1 1571/4885ALK 2361/4885FGFR1 109/4885 |
| US-11180495-B2 | Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof | CSF1R, CSF3R, FSHR | PDPK1 1571/4885ALK 2361/4885FGFR1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.